We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Half-Dose Depot Triptorelin Versus Reduced-Dose Daily Buserelin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00461916
Recruitment Status : Completed
First Posted : April 18, 2007
Last Update Posted : April 18, 2007
Information provided by:

April 17, 2007
April 18, 2007
April 18, 2007
May 2005
Not Provided
Number of retrieved oocytes
Same as current
No Changes Posted
  • Number of days of gonadotropin stimulation
  • Number of hMG ampoules
  • Number of follicles at hCG administration
  • Quality of oocytes
  • Quality of embryos
  • Poor response rate
  • Oocyte fertilization rate
  • Ineffective intervention rate
  • Clinical pregnancy rate
  • Implantation rate
  • Biochemical pregnancy rate
  • Multiple pregnancy rate
  • Miscarriage rate
  • Ectopic pregnancy rate
Same as current
Not Provided
Not Provided
Half-Dose Depot Triptorelin Versus Reduced-Dose Daily Buserelin
Half-Dose Depot Triptorelin Versus Reduced-Dose Daily Buserelin in a Long Protocol of Controlled Ovarian Stimulation for ICSI/ET
The purpose of this study is to determine whether half-dose depot triptorelin are as effective as reduced-dose daily buserelin in the controlled ovarian stimulation for intracytoplasmic sperm injection and embryo transfer

Significant doubts remain about which type of GnRH agonists [GnRHa] administration to be used in controlled ovarian stimulation [COS] cycles. The use of a single-dose depot long-acting GnRHa instead of a daily low dose preparation would be more comfortable for patients, however, inducing a profound pituitary desensitization, it increases the number of gonadotropin ampoules and the duration of the COS cycle without improving pregnancy rates or other clinical outcomes. Thus, some authors recommend a reduction of both dose and/or duration of GnRHa administration. Halving the dose of depot triptorelin, for instance, has been studied against its full dose administration since 1992 with rather similar clinical outcomes. Half-dose depot leuprolide acetate has also resulted in comparable clinical outcomes with standard daily injections in long GnRHa protocol. Reducing the daily doses of short acting GnRHa has been advocated to demonstrate equivalent results to standard doses. To our knowledge, however, the reduced daily doses have not been evaluated against half dose depot forms in long GnRHa protocols.

Thus, we originally compared a half-dose depot triptorelin with reduced daily doses of short-acting buserelin in a long protocol for intracytoplasmic sperm injection and embryo transfer [ICSI/ET] cycles.

Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
  • Drug: Half-Dose Depot Triptorelin
  • Drug: Reduced-Dose Daily Buserelin
Not Provided
Safdarian L, Mohammadi FS, Alleyassin A, Aghahosseini M, Meysamie A, Rahimi E. Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: a randomized double-blind clinical trial (NCT00461916). Hum Reprod. 2007 Sep;22(9):2449-54. Epub 2007 Jul 17.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2006
Not Provided

Inclusion Criteria:

  • Candidate for ICSI/ET
  • 35 years old or younger
  • Serum FSH less than 10 IU/l on day three of the previous menstrual cycle
  • No more than two previous IVF/ICSI attempts
  • No planned percutaneous epididymal sperm aspiration [PESA]
  • No planned testicular sperm extraction [TESE]
  • No known history or risk of severe hyperstimulation
  • No evidence of hydrosalpinx
  • No major systemic disease
  • No uterine abnormality
  • No previous ovarian surgery
Sexes Eligible for Study: Female
up to 35 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
Iran, Islamic Republic of
Not Provided
Not Provided
Not Provided
Tehran University of Medical Sciences
Not Provided
Principal Investigator: Leili Safdarian, MD Tehran University of Medical Sciences
Tehran University of Medical Sciences
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP